Report : Europe Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, and Other Drug Class); Route of Administration (Oral, Injections, Inhalation, and Other Route of Administration); Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy); and Country

Combination drug segment is expected to drive the growth of the Europe chronic cough market by drug class


According to the latest study on ‘Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class, Route of Administration, Distribution Channel, and Country,’ the Europe chronic cough market was valued at US$ 1,647.94 million in 2019 and is projected to reach US$  2,881.55 million by 2027; it is expected to grow at a CAGR of 7.3% during 2020–2027. The report highlights the trends prevailing in the Europe chronic cough market and the factors driving the market along with those that act as deterrents to its growth.


Based on drug class, the chronic cough market is segmented antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. In 2019, the combination drug segment accounted for the largest share of the Europe chronic cough market. The growth of the segment attributes to the to rising incidences of chronic cough, growing product developments to treat chronic cough are some of the primary factors contributing to the dominance of the segment in the Europe chronic cough market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the Europe n region. There are various government and non-government organizations working towards generating awareness among the people to reduce the use of chronic cough. For instance, the European Lung Foundation ELF is dedicated to lung health throughout Europe, and draws together the leading European medical experts to provide patient information and raise public awareness about respiratory disease. Furthermore, aging population is expected to drive demand for chronic cough treatment is likely to offer significant opportunities for the growth of the Europe  chronic cough market.


Novartis AG, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc., Bayer AG, Mylan N.V., Amneal Pharmaceuticals, Inc., Cipla Inc., Reckitt Benckiser Group plc., Sun Pharmaceutical Industries Ltd,

Aurobindo Pharma Ltd are among the prominent players present in the chronic cough market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in Mar 2018 GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business. GSK will buyout Novartis 36.5% stake in their Consumer Healthcare Joint Venture for US$13 billion (£9.2 billion).


Europe Chronic Cough Market, By Country, 2019 (%)

Europe Chronic Cough Market, By Country, 2019 (%)

The report segments the Europe chronic cough market as follows:

By Drug Class

  • Antihistamines
  • Corticosteroids
  • Decongestants
  • Combination Drug
  • Antibiotics
  • Acid Blockers
  • Other Drug Class

By Route of Administration

  • Oral
  • Injections
  • Nasal
  • Other Route of Administration

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Country

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id:     

Download Free PDF Brochure